Pharma ManufacturingMedium impactAfter close

Anupam Rasayan raises FY27 revenue growth guidance to over 30%

17 Aug 2026 · 16:04 ISTafter close1 source ↓written by the desknot a recommendation

: 20-25%

Anupam Rasayan India has increased its FY27 revenue growth guidance to over 30%, up from 20-25%. This growth is primarily driven by strong performance in the pharma and polymer sectors. The company also anticipates an upward bias in margins due to new product introductions and synergies from the Jayhawk acquisition. 📈

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 17 Aug 2026, 16:04 IST.

Sourcesnews.google.com

ANUPAMRASAYAN
Pharma
Manufacturing

Read inEN हिं తె मरा த ગુ

1 OctIndia raises anti-dumping duty on jute imports from BangladeshMediumIndia has increased anti-dumping duties on jute imports from Bangladesh and Nepal, aiming to protect domestic producers. This move may impact Bangladeshi exporters while benefiting India's jute industry through higher demand and improved capacity utilization.
1 OctHavells India valuation shifts signal price attractivenessMediumHavells India's PE ratio improved to 38.23, indicating enhanced valuation attractiveness compared to KEI Industries at 42.77. The EV/EBITDA ratio of 28.65 further supports its competitive position in the midcap sector.
1 OctJP Morgan identifies key sectors for India's growth cycleMediumJP Morgan's report identifies financials, private capital expenditure, and manufacturing as key growth themes in India. The firm favors mid- and small-cap stocks, with overweight allocations in several sectors, emphasizing the need for strong demand and capital expenditure.
1 OctAjanta Pharma promoters pledge shares for ₹3,873 crore debtMediumAjanta Pharma's promoters pledged 26,21,067 shares to secure ₹3,873 crore in debt instruments, comprising ₹3,373 crore from Lenexis Foodworks and ₹500 crore from Inspira Realty 2. This move may affect liquidity and investor sentiment.
1 OctIndia Inc's credit quality remains resilient in H1FY27MediumIndia Inc's credit quality remained resilient in H1FY27, with Crisil reporting a credit ratio of 2.18 times, up from 1.50 times in H2FY26. However, geopolitical tensions and rising crude prices may pressure credit profiles in H2FY27.
30 SeptVedanta approves ₹2,000 crore NCD allotmentMediumVedanta Limited approved the allotment of 2,00,000 unsecured, redeemable NCDs totaling ₹2,000 crore on 30 September 2026. Each debenture is priced at ₹1,00,000 and will be listed on the exchanges, enhancing liquidity for the company.

Anupam Rasayan raises FY27 revenue growth guidance to over 30%

Related